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z.2013.01Abstract Hepatocellular carcinoma (HCC) is the ﬁfth most common malignant tumor all over the
world. Although several treatments such as tumor resection and liver transplantation are used to
treat HCC, there is no overall long-term survival beneﬁt. Therefore, the need for therapy to prevent
the recurrence of HCC is essential. Curcumin and taurine have been used to participate in cancer
management such as HCC through activation of immune system. Mononuclear leukocytes (MNLs)
obtained from cirrhotic patients (n= 25), HCC patients (n= 25) and healthy volunteers (n= 25)
were included in this study. Cell density and percentage of CD4+, CD8+, and CD25+ of the MNLs
treated with curcumin and taurine were performed in addition to IFN-c level determined in their
cultured media. The results revealed that there was a highly signiﬁcant increase in MNLs’ density
of cirrhotic patients treated with curcumin and taurine. Where in HCC patients there were high sig-
niﬁcant increases in MNLs treated with curcumin and/or taurine. IFN-c level showed no signiﬁcant
increase in HCC, cirrhotic patients and controls. There were high signiﬁcant increases in percentage
of CD8+ of cirrhotic and HCC patients treated with curcumin and combination of curcumin and
taurine. But, percentage of CD4+ showed a high signiﬁcant decrease in cirrhotic and HCC patients
due to treatment with curcumin and/or taurine, on the contrary there were high signiﬁcant increases
in controls. Furthermore, there were high signiﬁcant increases in percentage of CD25+ of cirrhotic
patients and healthy controls treated with curcumin and/or taurine, but HCC patients showed no
signiﬁcant increase in percentage of CD25+ in MNLs treated with curcumin and/or taurine.
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.005Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
malignant tumor and the third leading cause of cancer-related
deaths worldwide (Behne and Copur, 2012). It is a primary
malignancy of the hepatocytes that accounts for approxi-he Egyptian German Society for Zoology.
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et al., 2011). HCC develops on a background of chronic liver
disease or inﬂammation and cirrhosis in 70–90% of all cases
(Cabibbo and Craxi, 2010).
The body has evolved active defenses that compose the im-
mune system. Although the immune system is composed of a
wide range of distinct cell types; lymphocytes play a central
role by providing the speciﬁcity of immune recognition (Wu
and Lanier, 2003). Lymphocyte with a CD4 has a speciﬁc
membrane molecule that differentiates it from a CD8 lympho-
cyte. CD4 T cells generally function as (TH) cells, and CD8 T
cells function as (TC) cells Blaney D., 2008. The tumor micro-
environment plays an important role in the establishment and
progression of tumors. Lymphocytes contribute to the tumor
microenvironment. CD8+ CTLs can directly kill target cells
by releasing granules including membrane-lytic materials such
as perforin and granzymes in acquired immune responses,
thereby playing a central role in antitumor immunity (Zhang
et al., 2003).
Curcumin (diferuloylmethane) is the chief component of
the spice turmeric and is derived from the rhizome of the East
Indian plant Curcuma longa (Sa and Das, 2008). Curcumin can
suppress cancer cell proliferation, induce apoptosis, inhibit
angiogenesis, and suppress the expression of anti-apoptotic
proteins but while protecting the immune system of the tumor
bearer it may have an untapped therapeutic value (Teiten
et al., 2010). Curcumin has been shown in last two decades
to be a potent immunomodulatory agent that can modulate the
activation of T cells, B cells, macrophages, neutrophils, natural
killer cells, and dendritic cells (Jagetia and Aggarwal, 2007).
Taurine, 2-aminoethanesulphonic acid is an essential amino
acid. Taurine has, also, been shown to have hepatoprotective
effects such as inhibition of extracellular matrix accumulation
in experimental liver ﬁbrosis (Issabeagloo et al., 2011). Taurine
and its derivatives such as taurolidine and taurochloramin
have been found to display antineoplastic effect both in vitro
and in vivo through suppressing cell proliferation and enhance-
ment of tumor cell apoptosis (Klamt and Shacter, 2005). Tau-
rine was reported to augment the proliferative responses of T-
lymphocytes from both young and old mice; however the aug-
mentation of the proliferative response by taurine was more in
old T cells than in young T cells (Negoro and Hara, 1992).
Methods
Patients
Seventy ﬁve individuals were included in this study and were
divided into three groups: GI: healthy controls’ group GII: cir-
rhotic patients’ group and GIII: HCC patients’ group. Each
group includes 25 subjects. All patient groups were presented
to the medical oncology clinic of the National Cancer Institute
(NCI), Cairo University, Egypt. We get our sample for the re-
search in my thesis from the sample of routine for patients in
the clinical department of national cancer institute.
Preparation of curcumin and taurine
Curcumin and taurine were supplied by Bio Basic INC. (Tro-
noto, Canada). Twenty lg of curcumin powder was dissolved
in 20 ml of DMSO (Dimethyle Sulfoxide) to obtain a ﬁnalconcentration of 1 lg/ml, concentration of the experiments
(0.5–5.0 lg/ml). The optimum concentration of curcumin is
0.5 lg/ml. One hundred and twenty ﬁve mg of taurine powder
was dissolved in 100 ml of RPMI media to obtain a ﬁnal con-
centration of 10 mmol/ml, concentration of the experiments
(1.0–10.0 mmol/ml). The optimum concentration of taurine is
5 mmol/ml. Curcumin and taurine solutions were ﬁltered using
syringe ﬁlters (pore size 0.45 lm) and stored at 20 C.
Peripheral blood mononuclear cell culture
Heparinized peripheral blood samples were obtained during
routine diagnostic procedures. Blood samples (3 ml) were di-
luted with equal volumes of phosphate buffered saline (Dul-
becco’s PBS), then overlaid on 3 ml of Ficoll-Hypaque
(Biochem, kg, Leonoemstr, Berlin) and centrifuged at 400g
for 30 min. The mononuclear leukocytes were washed twice
with phosphate buffered saline and plated in culture ﬂasks sup-
plemented with RPMI 1640 media (Sigma–Aldrich Co., USA)
containing 10% heat inactivated fetal calf serum (Biochrom,
Berlin, Germany) and 1% penicillin (10,000 U/ml), streptomy-
cin (10 mg/ml; Biochrom Berlin, Germany), and human Inter-
leukin-2 (IL-2) at a concentration of 2 ng/ml (invitrogen,
Carlsbad, USA) and each sample counted about one million/
ml and propagated ex-vivo at 37 C in an incubator with 5%
CO2 (pH= 7.4) for 48 h after that treated with curcumin
(0.5 lg/ml) and/or taurine (5mmole/ml) and divided into four
ﬂasks and counted before treatment. Mononuclear Leukocytes
(MNLs) harvested after 2 h and analyzed for immunopheno-
typing by a ﬂow cytometry and compared to untreated MNLs.
The conditioned media of MNLs were stored at 80 C for
IFN-c estimation.
Cell counting
Cell counting was done using hemocytometer by trypan blue
stain that could determine the cell concentration (cell density)
of living and dying cells. The dying cells were stained by trypan
blue, and appear blue under the microscope. Living cells ex-
clude trypan blue and appear white unstained.
Quantiﬁcation of IFN-c concentrations in cell cultured media
Cell culture supernatant samples (conditioned media) stored at
80 C until they were biochemically assayed. The samples
were examined to determine the level of IFN-c (Gamma
IFN (Bender Med systems GmbH, BMS228).
Flow cytometry
The surface phenotype of leukocytes generated from cirrhotic
patients and HCC patient cells was examined by ﬂow cytome-
try. Fluorochrome labeled monoclonal antibodies (mAbs)
were used to label the cells. The following mAbs were used:
CD4 (FITC IQ BB8.2), CD8 (PE IQ MCD8) and CD25 (PE
ACT-1) (all from Dako Ltd., Cambridge, UK).
Statistical analysis
Data were statistically described in terms of range, mean, stan-
dard deviation (±S.D.), frequencies (number of cases) and
182 S.H. Abdeen et al.relative frequencies (percentages) when appropriate using what
is so called ‘Descriptive statistics’. Comparison of variables be-
tween the study groups was done using analysis of variance
(ANOVA) test as illustrated in demographic data and clinical
features of patient groups and healthy controls. For compar-
ing categorical data, Chi square (v2) test was performed such
as case of examination of the relation between qualitative vari-
ables of males and females in sex parameter. Multiple regres-
sion analysis was also performed for untreated and treated
cells in all levels of the current study using regression test. A
probability value (P-value) less than 0.05 was considered sta-
tistically signiﬁcant. Statistical calculations were done using
statistical computer program: SPSS (Statistical Package for
the Social Science; SPSS Inc., Chicago, IL, USA, version 17.0).Results
The present results revealed the effect of curcumin and taurine
in separate and in combination on cell density, levels of IFN-c
concentration, and immunophenotyping characterization of
MNLs isolated from presented three groups controls, cirrhotic
patients, and HCC patients. IL-2 was used as a growth factor
in culture media of MNLs obtained from the previous men-
tioned groups.
The effect of curcumin and taurine on the cell density
At the level of the cell density in the control group (n= 25),
there were high signiﬁcant increases (P= 0.001) in MNLs un-
treated compared with MNLs treated with curcumin, MNLs
treated with taurine, and MNLs treated with combination of
curcumin and taurine. In the cirrhotic patients’ groupFig. 1 The effect of curcumin and taurine on cellular density of MN
data expressed as (mean ± SD).(n= 25), there were no signiﬁcant increases (P= 0.05) in
MNLs untreated compared to MNLs treated with curcumin
and MNLs treated with taurine. But there was a signiﬁcant in-
crease (P= 0.012) in MNLs untreated compared to MNLs
treated with combination of curcumin and taurine. In the
HCC patients’ group (n= 25), there was a moderate signiﬁ-
cant increase (P= 0.007) in MNLs untreated compared to
MNLs treated with curcumin, and there were high signiﬁcant
increases (P= 0.001) in MNLs untreated compared to MNLs
treated with taurine and MNLs treated with combination of
curcumin and taurine. While, when comparing the control
group with the cirrhotic patients’ group, there were high signif-
icant increases (P= 0.001) in MNLs untreated, treated with
curcumin, treated with taurine, and treated with combination
of curcumin and taurine. In case of the control group com-
pared to the HCC patients’ group, there were high signiﬁcant
increases (P= 0.001) in MNLs untreated, treated with curcu-
min, treated with taurine, treated with combination of curcu-
min and taurine as shown in (Fig. 1).
The effect of curcumin and taurine on IFN-c in conditioned
media
In the control group (n= 25), cirrhotic patients’ group
(n= 25), and HCC patients’ group (n= 25), there were no
signiﬁcant increases (P= 0.05) in MNLs untreated compared
to MNLs treated with curcumin, treated with taurine, and
MNLs treated with combination of curcumin and taurine,
while, when comparing the control group with the cirrhotic pa-
tients’ group, there were no signiﬁcant increases (P= 0.05),
but when comparing control with the HCC patients’ group
there were high signiﬁcant increases (P= .001) as shown in (
Fig. 2).Ls on healthy controls, cirrhotic patients, and HCC patients. The
Fig. 2 The effect of curcumin and taurine on IFN-c level in conditioned media of MNLs isolated from healthy controls, cirrhotic
patients and HCC patients. The data expressed as (mean ± SD).
Fig. 3 The effect of curcumin and taurine on CD4+ helper T cells’ expression in MNLs of healthy controls, cirrhotic patients, and HCC
patients. The data expressed as (mean ± SD).
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For CD4+ T helper cells’ expression, in the control group,
there was a moderate signiﬁcant increase (P= 0.025) in
MNLs untreated compared to MNLs treated with curcumin,
and there were high signiﬁcant increases (P= 0.001) in MNLs
untreated compared to MNLs treated with taurine, and MNLs
treated with combination of curcumin and taurine. In the cir-
rhotic patients’ group, there was a signiﬁcant decrease(P= 0.020) in MNLs untreated compared to MNLs treated
with curcumin, and a high signiﬁcant decrease (P= 0.001) in
MNLs untreated compared to MNLs treated with combina-
tion of curcumin and taurine, but, there was no signiﬁcant in-
crease (P= 0.05) in MNLs untreated compared to MNLs
treated with taurine. In case of the HCC patients’ group, there
was a moderate signiﬁcant decrease (P= 0.048; P= 0.035
respectively) in MNLs untreated compared to MNLs treated
with curcumin and treated with taurine, where there was a high
Fig. 4 The effect of curcumin and taurine on CD8+ cytotoxic T cells’ expression in MNLs of healthy controls, cirrhotic patients, and
HCC patients. The data expressed as (mean ± SD).
Fig. 5 The effect of curcumin and taurine on CD25+ (IL-2 receptor) expression in MNLs of healthy controls, cirrhotic patients, and
HCC patients. The data expressed as (mean ± SD).
184 S.H. Abdeen et al.signiﬁcant decrease (P= 0.001) in MNLs untreated compared
to MNLs treated with combination of curcumin and taurine.
While, when comparing the control group with the cirrhotic
patients’ group there were high signiﬁcant increases
(P= 0.001), and when comparing the control group with the
HCC patients’ group, there were high signiﬁcant increases
(P= 0.001) in MNLs untreated, MNLs treated with curcu-
min, MNLs treated with taurine, but there was no signiﬁcantincrease (P= 0.05) in MNLs treated with combination of cur-
cumin and taurine as shown in (Fig. 3).
The effect of curcumin and taurine on CD8+ percentage
In case of CD8+ cytotoxic T cells’ expression, in the control
group, there were high signiﬁcant increases (P= 0.001) in
MNLs untreated compared to MNLs treated with curcumin,
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tion of curcumin and taurine. In case of the cirrhotic patients’
group, there was a moderate signiﬁcant increase (P= 0.006) in
MNLs untreated compared to MNLs treated with curcumin,
and there was a high signiﬁcant increase (P= 0.001) in MNLs
untreated compared to MNLs treated with combination of
curcumin and taurine, but there was no signiﬁcant increase
(P= 0.05) in MNLs untreated compared to MNLs treated
with taurine. In case of the HCC patients’ group, there was
a moderate signiﬁcant increase (P= 0.026) in MNLs un-
treated compared to MNLs treated with curcumin, and a high
signiﬁcant increase (P= 0.001) in MNLs untreated compared
to MNLs treated with combination of curcumin and taurine,
but there was no signiﬁcant increase (P= 0.05) in MNLs un-
treated compared to MNLs treated with taurine. While, when
comparing the control group with the cirrhotic patients’ group,
there were high signiﬁcant increases (P= 0.001), and when
comparing the control group with the HCC patients’ group,
there were no signiﬁcant increases (P= 0.05) in MNLs un-
treated and MNLs treated with curcumin, but there were high
signiﬁcant increases (P= 0.001) in MNLs treated with taurine
and MNLs treated with combination of curcumin and taurine
as shown in (Fig. 4).
The effect of curcumin and taurine on CD25+ percentage
In case of CD25+ expression (IL-2 receptor) in the control
group, there were high signiﬁcant increases (P= 0.001) in
MNLs untreated compared to MNLs treated with curcumin,
MNLs treated with taurine, and MNLs treated with curcumin
and taurine. In the cirrhotic patients’ group, there were high
signiﬁcant increases (P= 0.001) in MNLs untreated compared
to MNLs treated with curcumin, MNLs treated with taurine,
and MNLs treated with combination of curcumin and taurine.
In the HCC patients’ group, there were no signiﬁcant increases
(P= 0.05) in MNLs untreated compared to MNLs treated
with curcumin, MNLs treated with taurine, and MNLs treated
with combination of curcumin and taurine. While, when com-
paring the control group with the cirrhotic patients’ group,
there were high signiﬁcant increases (P= 0.001), and when
comparing the control group with the HCC patients’ group,
there were high signiﬁcant increases (P= 0.001; P= 0.002;
P= 0.003, respectively) in MNLs untreated, MNLs treated
with curcumin, and MNLs treated with taurine, but there
was no signiﬁcant increase (P= 0.05) in MNLs treated with
combination of curcumin and taurine as shown in (Fig. 5).Discussion
The present study showed an increase in lymphocyte prolifer-
ation when treated with curcumin and/or taurine in HCC pa-
tients and controls compared to untreated lymphocytes. Where
in the cirrhotic patients lymphocyte proliferation increased
only in combination of curcumin and taurine, and this results
supported by the studies which have revealed that curcumin
enhances T cell proliferation capacity in the long term, which
may restore the numbers of T cells in vivo in tumor bearing
hosts. Also, it has been demonstrated that tumor-induced
depletion of T cells can be reserved by dietary curcumin
in vivo (Varalakshmi et al., 2008). In addition, it was suggested
that curcumin helps in T cell survival both in primary andeffector immune compartments of tumor bearing hosts by nor-
malizing perturbed Jak/Stats activity via restoration of IL-2
receptor cc chain expression (Sa and Das, 2008). Furthermore,
the study observed that curcumin had a signiﬁcant cytotoxic
effect on acute myeloid leukemia cell line and signiﬁcantly
inhibited proliferation of these cells in AML patients but it
had no side effects on normal mononuclear leukocytes isolated
from the peripheral blood of healthy donors (Rao et al., 2011).
Additionally, the present study is supported by a study which
reported that when taurine is used in conjunction with chemo-
therapy it improves tumor inhibition rates by increasing the
count and classiﬁcation of white blood cells, improving lym-
phocyte proliferation and macrophage phagocytic capabilities,
and elevated measures of spleen and thymus function in cancer
bearing mice (Goodman et al., 2009). Also, it has been re-
ported that taurine and taurine transporter play a role in lym-
phoproliferation. It was observed that lymphocytes of male
Sprague–Dawley rats, stressed by physical restrain and con-
trols which were isolated from the blood, and then cultured
in the presence of taurine (12 mM) signiﬁcantly increased lym-
phoproliferation of these cells (Fazzino et al., 2010). Further-
more, it has been shown that taurine stimulates T and B
lymphocytes in response to mitogens and increases cytoplas-
mic Ca+2 concentration in these cells, because the regulation
of intracellular calcium level is intimately related to lympho-
cyte activation (Hussy et al., 2000).
On the other hand, for INF- c released in condition media
of propagated ex-vivo cells in the present study showed that
there was no signiﬁcant effect in Mononuclear Leukocytes
(MNLs) treated with curcumin and/or taurine compared to
untreated MNLs in controls, cirrhotic patients, and HCC pa-
tients. The present study is supported by a study that showed
that curcumin inhibits IFN-c, which is induced by Stat 1 phos-
phorylation (Zhou et al., 2011). Furthermore, for taurine, it
has been observed that treatment of Mononuclear Leukocytes
(MNLs) with taurine for 48 h did not affect the IFN-c level in
their conditioned media (Wirleitner et al., 2004).
Where in case of CD4+ the results showed a highly signif-
icant increase in the percentage of CD4+ MNLs treated with
curcumin and/or taurine when compared with MNLs un-
treated in controls. But there was a highly signiﬁcant decrease
in cirrhotic patients and HCC patients. The data presented for
control are supported by several studies which suggested that
curcumin enhances immunity by stimulating the CD4+ T-
helper cells and B lymphocyte (Mishra et al., 2008), while
the data for cirrhotic and HCC are not in agreement with this
study.
Also, another study agrees with the data presented for con-
trol in the study which reported that curcumin signiﬁcantly in-
creased the percentage of CD4+ cells obtained from rat blood
samples after oral administration of the toxic materials 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD). The authors reported
that curcumin showed immunomodulatory effects and elimi-
nated TCDD-induced immune suppressive effects in rats (Cif-
tci et al., 2010), while the data for cirrhotic and HCC are not in
agreement with this study.
Where, for taurine the data presented for control are sup-
ported by several studies which observed that CD4+ T cells
signiﬁcantly decreased in taurine transporter deﬁcient mice
compared with taurine transporter presenting mice following
in vivo activation (Kaesler et al., 2012). While the data for cir-
rhotic and HCC are not in agreement with this study.
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cant increases in MNLs untreated and treated with curcumin
and/or taurine in cirrhotic patients compared to controls and
HCC patients. However, when comparing HCC with controls,
there is a highly signiﬁcant increase in MNLs treated with tau-
rine and combination of curcumin and taurine. While in each
group in cirrhotic patients and HCC patients there is a highly
signiﬁcant increase in MNLs treated with curcumin and com-
bination of curcumin and taurine. However, there was no sig-
niﬁcant effect in MNLs treated with taurine compared to
untreated. In controls there were high signiﬁcant increases in
MNLs treated with curcumin and/ or taurine compared to un-
treated MNLs.
The present study is supported by another that showed ben-
eﬁcial effects of curcumin may improve the therapeutic efﬁcacy
of adoptive therapy. The authors showed that curcumin en-
hanced cytotoxicity of CD8+ T cells toward tumors via alter-
ation of the tumor microenvironment when combined with
adoptive therapy in mice (Chang et al., 2012). Also, it has been
reported that a low-dose of curcumin increased T cells derived
from all tumor-bearing mice, especially CD8+ T cells. These
increased CD8+ T cells exhibited the enhancement of IFN-c
secretion, proliferation and cytotoxicity against all tumor cells,
which may result in the success of anti-tumor immunity (Luo
et al., 2011). Additionally, for taurine it has been observed that
CD8+ T cells signiﬁcantly decreased in taurine transporter
deﬁcient mice compared with taurine transporter presenting
mice following in vivo activation. These ﬁndings revealed the
importance of taurine in CD8+ T cells’ activation (Kaesler
et al., 2012).
On other hand, in case of CD25+ proﬁle showed a signiﬁ-
cant increase in MNLs treated with curcumin and/or taurine in
cirrhotic patients and controls compared to untreated, but not
in HCC patients. The present study disagrees with another
which revealed that curcumin exerts some of its immunomod-
ulatory effects on mouse forkhead box P3 (Foxp3), and CD25
expression; inhibiting IL-2 receptor (IL-2R)-mediated phos-
phorylation of signal transducer and activator of transcription
5A and janus kinase 3; and down regulating the suppressor
function of CD4+CD25+ regulatory T-cells. This could be
due to estimate the estimation of the percentage of CD25+
alone not expressed with CD4+ the present study (Forward
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